Good value ACEi
ACE inhibitors are cost-effective for treating the vast majority of patients with stable coronary artery disease, a new study
An economic analysis of results from the EUROPA trial found perindopril fell within NICE cost-effectiveness thresholds for more than 90 per cent of patients, despite a wide variation in cardiovascular risk.
In 97 per cent of patients cost per quality-adjusted life year was below £30,000 'the apparent threshold used by NICE' and cost per QALY was below £20,000 in 89 per cent of patients.
Study leader Professor Andrew Briggs, professor of health policy and health economics at the University of Glasgow, said: 'The estimated mean was about £10,000. You would be hard pushed to find anyone who thinks that £10,000 doesn't offer good value for money.'
Professor Briggs, whose research was presented at the British Cardiac Society conference in Glasgow this week, added: 'PCTs will be very interested in what this means for eligible populations. We would hope that if you showed something was value for money, it would at least encourage people to think about using it.'